Medical technology company Inogen Inc (Nasdaq: INGN) announced on Monday that it has received FDA 510(k) clearance for the SIMEOX 200 Airway Clearance Device, enabling its introduction to the US market.
This next-generation device builds on the original Simeox, currently available internationally, to enhance bronchial drainage for patients with chronic respiratory diseases like Bronchiectasis, COPD, Cystic Fibrosis and Primary Ciliary Dyskinesia.
SIMEOX 200 uses high-frequency oscillatory vibrations and intermittent negative pressure during exhalation to mobilize bronchial secretions effectively, offering an innovative alternative to traditional airway clearance therapies. Designed for use in healthcare settings or at home, it is aimed at patients capable of independently generating a cough.
Inogen plans a limited US launch of the device in 2025, targeting specific sites. As a global leader in respiratory technology, Inogen continues to expand its portfolio of innovative homecare solutions, supporting patients and healthcare providers with advanced respiratory therapies.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933